HIST1H2BJ is associated with poor prognosis and an immune-altered tumor microenvironment in glioma. (PubMed, Front Immunol) - Oct 2, 2026 - "Furthermore, molecular docking identified VX-680 and A.770041 as candidate compounds associated with HIST1H2BJ-high drug-sensitivity prediction; their direct binding to HIST1H2BJ was assessed only in silico by molecular docking and dynamics simulations and requires experimental validation. This study establishes HIST1H2BJ as an independent prognostic factor for glioma patient survival and a candidate prognostic biomarker whose therapeutic relevance requires further functional and preclinical investigation."
Biomarker • Journal • Brain Cancer • Glioma • Oncology • Solid Tumor • CD8
|
|
Chen Shi; Chiwen Qu; Lupeng Zhang; Ruijuan Liu; Sihua Peng; Xiaoning Peng; Yong Zhang; Yue Li
|